Log in

NYSE:USNAUSANA Health Sciences Stock Price, Forecast & News

$84.72
-0.47 (-0.55 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$83.16
Now: $84.72
$85.02
50-Day Range
$66.91
MA: $79.54
$89.22
52-Week Range
$43.01
Now: $84.72
$90.94
Volume156,754 shs
Average Volume252,944 shs
Market Capitalization$1.78 billion
P/E Ratio18.26
Dividend YieldN/A
Beta0.94
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensé—beautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Read More
USANA Health Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryPersonal Products
SectorMedical
CUSIP90328M10
Phone801-954-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.06 billion
Cash Flow$5.75 per share
Book Value$15.11 per share

Profitability

Net Income$100.53 million

Miscellaneous

Employees1,909
Market Cap$1.78 billion
Next Earnings Date7/28/2020 (Estimated)
OptionableOptionable

Receive USNA News and Ratings via Email

Sign-up to receive the latest news and ratings for USNA and its competitors with MarketBeat's FREE daily newsletter.

USANA Health Sciences (NYSE:USNA) Frequently Asked Questions

How has USANA Health Sciences' stock been impacted by COVID-19 (Coronavirus)?

USANA Health Sciences' stock was trading at $69.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, USNA shares have increased by 21.2% and is now trading at $84.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of USANA Health Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for USANA Health Sciences.

When is USANA Health Sciences' next earnings date?

USANA Health Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for USANA Health Sciences.

How were USANA Health Sciences' earnings last quarter?

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings results on Tuesday, April, 21st. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.66. The firm had revenue of $266.62 million for the quarter, compared to analysts' expectations of $220.40 million. USANA Health Sciences had a return on equity of 30.09% and a net margin of 9.76%. The company's quarterly revenue was down 2.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.01 EPS. View USANA Health Sciences' earnings history.

How will USANA Health Sciences' stock buyback program work?

USANA Health Sciences announced that its board has approved a share repurchase program on Wednesday, February 5th 2020, which allows the company to repurchase $130,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 9.1% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.

What guidance has USANA Health Sciences issued on next quarter's earnings?

USANA Health Sciences issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, April, 21st. The company provided EPS guidance of 4.00-4.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.01. The company issued revenue guidance of $1-1.08 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for USNA?

4 Wall Street analysts have issued twelve-month price targets for USANA Health Sciences' shares. Their forecasts range from $65.00 to $75.00. On average, they expect USANA Health Sciences' stock price to reach $70.00 in the next twelve months. This suggests that the stock has a possible downside of 17.4%. View analysts' price targets for USANA Health Sciences.

What are Wall Street analysts saying about USANA Health Sciences stock?

Here are some recent quotes from research analysts about USANA Health Sciences stock:
  • 1. According to Zacks Investment Research, "USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company's three primary product lines consist of nutritional, personal care and weight management products. The company's products are distributed primarily through a network marketing system. " (5/3/2020)
  • 2. Pivotal Research analysts commented, "We thought it noteworthy that the company projected average diluted shares outstanding of 22.7 million, given that 2Q diluted shares out were 23.4 million. To get to that average we expect the company will need to buy-in 1.9 million shares in the 2H. That will put average shares outstanding down 7.7% for the year. This is not so important for 2019, but it will be for next year when we see an earnings recovery of 27% at the net income line (still below 2018) but EPS growth of 38% owing to the reduced share count." (7/24/2019)

Has USANA Health Sciences been receiving favorable news coverage?

News headlines about USNA stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. USANA Health Sciences earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the near future. View the latest news aboutUSANA Health Sciences.

Are investors shorting USANA Health Sciences?

USANA Health Sciences saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,570,000 shares, a drop of 16.0% from the April 30th total of 1,870,000 shares. Based on an average trading volume of 268,900 shares, the short-interest ratio is presently 5.8 days. Currently, 13.0% of the company's stock are sold short. View USANA Health Sciences' Current Options Chain.

Who are some of USANA Health Sciences' key competitors?

What other stocks do shareholders of USANA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include IBM (IBM), Gilead Sciences (GILD), AT&T (T), Allergan (AGN), AbbVie (ABBV), Amgen (AMGN), Intel (INTC), Intuitive Surgical (ISRG), NVIDIA (NVDA) and Tesla (TSLA).

Who are USANA Health Sciences' key executives?

USANA Health Sciences' management team includes the following people:
  • Dr. Myron W. Wentz, Founder & Chairman (Age 78)
  • Mr. Kevin G. Guest, CEO & Director (Age 56)
  • Mr. Jim Brown, Pres & COO (Age 50)
  • Mr. G. Douglas Hekking, Chief Financial Officer (Age 49)
  • Mr. Walter Noot, Chief Information Officer (Age 53)

What is USANA Health Sciences' stock symbol?

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

Who are USANA Health Sciences' major shareholders?

USANA Health Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.02%), Acadian Asset Management LLC (3.68%), State Street Corp (2.01%), Morgan Stanley (1.05%), Morgan Stanley (1.05%) and Geode Capital Management LLC (1.04%). Company insiders that own USANA Health Sciences stock include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert A Sinnott, Robert Auciaux and Walter Noot. View institutional ownership trends for USANA Health Sciences.

Which institutional investors are selling USANA Health Sciences stock?

USNA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, AQR Capital Management LLC, BlackRock Inc., JPMorgan Chase & Co., MERIAN GLOBAL INVESTORS UK Ltd, Martingale Asset Management L P, Parametric Portfolio Associates LLC, and Aigen Investment Management LP. Company insiders that have sold USANA Health Sciences company stock in the last year include Brent Neidig, Daniel A Macuga, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert Auciaux, and Walter Noot. View insider buying and selling activity for USANA Health Sciences.

Which institutional investors are buying USANA Health Sciences stock?

USNA stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, APG Asset Management N.V., APG Asset Management N.V., APG Asset Management N.V., Morgan Stanley, Morgan Stanley, Mackay Shields LLC, and Bogle Investment Management L P DE. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull, and Myron W Wentz. View insider buying and selling activity for USANA Health Sciences.

How do I buy shares of USANA Health Sciences?

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is USANA Health Sciences' stock price today?

One share of USNA stock can currently be purchased for approximately $84.72.

How big of a company is USANA Health Sciences?

USANA Health Sciences has a market capitalization of $1.78 billion and generates $1.06 billion in revenue each year. The company earns $100.53 million in net income (profit) each year or $4.41 on an earnings per share basis. USANA Health Sciences employs 1,909 workers across the globe.

What is USANA Health Sciences' official website?

The official website for USANA Health Sciences is www.usana.com.

How can I contact USANA Health Sciences?

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.